Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 1.00 |
| ▸ | NPC1 | O15118 | 9/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2247920 | 0.88 | RAB9A (1.00) | RAB9ANPC1TP53SMN1; SMN2MAPT | |
| SCHEMBL2247503 | 0.87 | RAB9A (0.81) | RAB9ANPC1TP53SMN1; SMN2MAPT | |
| SCHEMBL2245364 | 0.86 | RAB9A (0.78) | RAB9ANPC1TP53SMN1; SMN2MAPT | |
| SCHEMBL14451614 | 0.86 | RAB9A (0.78) | RAB9ANPC1TP53SMN1; SMN2MAPT | |
| SCHEMBL14451616 | 0.82 | RAB9A (0.72) | RAB9ANPC1TP53SMN1; SMN2MAPT | |
| SCHEMBL6966171 | 0.82 | RAB9A (0.72) | RAB9ANPC1TP53SMN1; SMN2MAPT | |
| SCHEMBL4725005 | 0.81 | RAB9A (0.75) | RAB9ANPC1TP53SMN1; SMN2PPARG | |
| SCHEMBL6800275 | 0.80 | RAB9A (0.69) | RAB9ANPC1TP53SMN1; SMN2MAPT | |
| SCHEMBL4763335 | 0.79 | RAB9A (0.67) | RAB9ANPC1TP53SMN1; SMN2MAPT | |
| SCHEMBL9472171 | 0.78 | RAB9A (0.66) | RAB9ANPC1TP53SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189477-A1 | Methods and Compositions of P27KIP1 Transcriptional Modulators | NIH-DEITR | 2017-07-06 | — | — | US | claimed |
| US-9572815-B2 | Methods and compositions of p27KIP1 transcriptional modulators | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-02-21 | — | — | US | claimed |
| WO-2014145205-A2 | METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTION MODULATORS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-09-18 | — | — | WO | claimed |
| EP-2254572-B1 | COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION | MASSACHUSETTS EYE & EAR INFIRM (US) | 2013-10-16 | — | — | EP | claimed |
| US-8188131-B2 | Compounds that enhance Atoh1 expression | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2012-05-29 | — | — | US | claimed |
| US-20090232780-A1 | COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2009-09-17 | — | — | US | claimed |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2025-03-27 | — | — | US | disclosed |
| US-12239651-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-03-04 | — | — | US | disclosed |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2024-09-12 | — | — | US | disclosed |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-07-23 | — | — | US | disclosed |
| US-11963968-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240100079-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS IN THE INNER EAR OF ADULT MAMMALS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-28 | — | — | US | disclosed |
| US-20120328580-A1 | COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION | MASSACHUSETTS EYE & EAR INFIRMARY | 2012-12-27 | — | — | US | disclosed |
| US-8188131-B2 | Compounds that enhance Atoh1 expression | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188131-B2 | Compounds that enhance Atoh1 expression | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188131-B2 | Compounds that enhance Atoh1 expression | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090232780-A1 | COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090232780-A1 | COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090232780-A1 | COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | HES1, NOTCH1, NOTCH4 | RAB9A 1434/4885NPC1 1607/4885TP53 417/4885 |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | HES1, NOTCH1, NOTCH2 | RAB9A 2455/4885NPC1 1630/4885TP53 94/4885 |
| US-20170189477-A1 | Methods and Compositions of P27KIP1 Transcriptional Modulators | WNT1, CTNNB1, CTNNBL1 | RAB9A 4314/4885NPC1 1011/4885TP53 16/4885 |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | HES1, NOTCH1, NOTCH4 | RAB9A 3020/4885NPC1 1656/4885TP53 57/4885 |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | HES1, NOTCH1, NOTCH4 | RAB9A 3020/4885NPC1 1656/4885TP53 57/4885 |
| US-20090232780-A1 | COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION | DACH1, EZH1, CREBBP | RAB9A 3293/4885NPC1 1018/4885TP53 740/4885 |
| US-20120328580-A1 | COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION | DACH1, EZH1, CREBBP | RAB9A 3293/4885NPC1 1018/4885TP53 740/4885 |
| US-12239651-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | RAB9A 1434/4885NPC1 1607/4885TP53 417/4885 |
| US-11963968-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | RAB9A 1434/4885NPC1 1607/4885TP53 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.